Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Lung Cancer. 2016 Aug 8;18(1):34–42.e2. doi: 10.1016/j.cllc.2016.07.007

Table 3.

Drug-Related Adverse Events Reported in ≥10% of Patients in Either Treatment Group

Adverse Event, n (%) Linsitinib + Erlotinib (N = 43) Placebo + Erlotinib (N = 44)
Grade 1/2 Grade 3 Grade 4 Grade 1/2 Grade 3 Grade 4
Overall 21 (48.8) 20 (46.5) 2 (4.7) 34 (79.1) 10 (22.7) 0
Skin rash 33 (76.7) 3(7.0) 0 40 (90.9) 3 (6.8) 0
Diarrhea 28 (65.1) 1 (2.3) 0 29 (65.9) 4 (9.1) 0
Dry skin 20 (46.5) 0(0) 0 18 (40.9) 0 0
Fatigue 12 (27.9) 4 (9.3) 0 15 (34.1) 1 (2.3) 0
Nausea 15 (34.9) 4 (9.3) 0 12 (27.3) 0 0
Decreased appetite 16 (37.2) 2 (4.7) 0 8 (18.2) 1 (2.3) 0
Paronychia 8 (18.6) 0 0 14 (31.8) 0 0
Alopecia 5 (11.6) 0 0 14 (31.8) 0 0
Stomatitis 11 (25.6) 0 0 7 (15.9) 0 0
Vomiting 11 (25.6) 2 (4.7) 0 4 (9.1) 0 0
Pruritus 4 (9.3) 0 0 12 (27.3) 0 0
Increased ALT 3(7.0) 9 (20.9) 2 (4.7) 0 1 (2.3) 0
Increased AST 7 (16.3) 5 (11.6) 0 1 (2.3) 0 0
Dysgeusia 7 (16.3) 0 0 6 (13.6) 0 0
Dry eye 7 (16.3) 0 0 5 (11.4) 0 0
Hyperglycemia 7 (16.3) 1 (2.3) 0 1 (2.3) 0 0
Dry mouth 5 (11.6) 0 0 3 (6.8) 0 0
Increased blood bilirubin 6 (14.0) 1 (2.3) 0 0 0 0
Decreased weight 4 (9.3) 1 (2.3) 0 2 (4.5) 0 0
Increased blood creatinine 5 (11.6) 0 0 0 0 0
Skin fissures 0 0 0 5 (11.4) 0 0

Abbreviations: ALT = Alanine aminotransferase; AST = aspartate aminotransferase.